Biohaven Pharmaceutical Holding Co Ltd (BHVN) Given Average Recommendation of “Buy” by Analysts

Shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) have been assigned a consensus recommendation of “Buy” from the eleven analysts that are covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $65.39.

BHVN has been the topic of a number of research reports. Oppenheimer cut their target price on shares of Biohaven Pharmaceutical from $63.00 to $54.00 and set an “outperform” rating on the stock in a research note on Friday, December 28th. Zacks Investment Research raised shares of Biohaven Pharmaceutical from a “hold” rating to a “buy” rating and set a $40.00 target price on the stock in a research note on Tuesday, January 15th. ValuEngine raised shares of Biohaven Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Monday, February 4th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $75.00 target price on shares of Biohaven Pharmaceutical in a research note on Friday, February 8th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $56.00 target price (up previously from $48.00) on shares of Biohaven Pharmaceutical in a research note on Monday, March 4th.

In other news, CEO Vlad Coric sold 100,000 shares of Biohaven Pharmaceutical stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $50.09, for a total transaction of $5,009,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Declan Doogan sold 40,000 shares of Biohaven Pharmaceutical stock in a transaction dated Wednesday, February 13th. The shares were sold at an average price of $44.31, for a total transaction of $1,772,400.00. The disclosure for this sale can be found here. Insiders have sold a total of 310,206 shares of company stock worth $14,996,874 in the last ninety days. Insiders own 34.20% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of BHVN. Stifel Financial Corp lifted its position in Biohaven Pharmaceutical by 555.2% during the 4th quarter. Stifel Financial Corp now owns 2,719,538 shares of the company’s stock valued at $100,569,000 after acquiring an additional 2,304,438 shares during the period. Brown Advisory Inc. purchased a new position in Biohaven Pharmaceutical during the 4th quarter valued at about $16,766,000. TIAA CREF Investment Management LLC lifted its position in Biohaven Pharmaceutical by 670.0% during the 3rd quarter. TIAA CREF Investment Management LLC now owns 463,254 shares of the company’s stock valued at $17,395,000 after acquiring an additional 403,092 shares during the period. Aisling Capital Management LP purchased a new position in Biohaven Pharmaceutical during the 4th quarter valued at about $10,151,000. Finally, Samlyn Capital LLC lifted its position in Biohaven Pharmaceutical by 32.8% during the 4th quarter. Samlyn Capital LLC now owns 921,536 shares of the company’s stock valued at $34,078,000 after acquiring an additional 227,432 shares during the period. 88.91% of the stock is owned by institutional investors.

Biohaven Pharmaceutical stock traded up $1.68 during trading hours on Monday, reaching $59.92. The stock had a trading volume of 1,039,529 shares, compared to its average volume of 518,685. The firm has a market cap of $2.60 billion, a PE ratio of -9.74 and a beta of 0.50. Biohaven Pharmaceutical has a 52 week low of $25.60 and a 52 week high of $60.95.

Biohaven Pharmaceutical (NYSE:BHVN) last announced its quarterly earnings results on Thursday, February 28th. The company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.06). As a group, sell-side analysts expect that Biohaven Pharmaceutical will post -6.16 earnings per share for the current year.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.

Read More: Balanced Fund

Analyst Recommendations for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.